Cosentyx Approved for Pediatric Plaque Psoriasis
The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque psoriasis who were candidates for systemic therapy.
Diagnosis & Disease Information
Repigmentation Observed With Ruxolitinib Cream in Vitiligo Trials
Results from both studies demonstrated that ruxolitinib met the primary endpoint with a greater proportion of patients achieving F-VASI75 at week 24.
FDA Approves Rx-to-OTC Switch of Sklice for Head Lice Treatment
Each gram of lotion contains 5mg of ivermectin, the same as the prescription strength.
- Loading...
Loading...
Next post in News
Loading... 
Loading...